FENC Logo

Fennec Pharmaceuticals Inc. (FENC) 

NASDAQ
Market Cap
$164.29M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
414 of 960
Rank in Industry
250 of 550

Largest Insider Buys in Sector

FENC Stock Price History Chart

FENC Stock Performance

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Insider Activity of Fennec Pharmaceuticals Inc.

Over the last 12 months, insiders at Fennec Pharmaceuticals Inc. have bought $0 and sold $3.79M worth of Fennec Pharmaceuticals Inc. stock.

On average, over the past 5 years, insiders at Fennec Pharmaceuticals Inc. have bought $2.65M and sold $1.6M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 29,167 shares for transaction amount of $0 was made by Raykov Rosty (CHIEF EXECUTIVE OFFICER) on 2024‑04‑01.

List of Insider Buy and Sell Transactions, Fennec Pharmaceuticals Inc.

2024-12-05Saledirector
796
0.003%
$6.04$4,808+6.12%
2024-12-03Saledirector
1,635
0.0059%
$6.13$10,023-2.57%
2024-12-02Saledirector
6,409
0.0225%
$6.14$39,351-2.72%
2024-11-04Saledirector
2,431
0.0082%
$4.31$10,478+28.82%
2024-10-08Saledirector
1,406
0.0045%
$4.53$6,369+4.66%
2024-10-01Saledirector
2,431
0.0085%
$4.94$12,009-3.53%
2024-09-04Saledirector
2,431
0.0088%
$5.52$13,419-8.09%
2024-08-01SaleCHIEF EXECUTIVE OFFICER
2,431
0.0089%
$6.25$15,206-15.39%
2024-07-05Saledirector
1,173
0.0043%
$6.03$7,0730.00%
2024-07-02SaleCHIEF EXECUTIVE OFFICER
2,431
0.0091%
$6.13$14,9020.00%
2024-06-03SaleCHIEF EXECUTIVE OFFICER
2,431
0.0089%
$6.76$16,434-16.22%
2024-05-01SaleCHIEF EXECUTIVE OFFICER
2,431
0.009%
$9.11$22,152-34.47%
2024-04-22SaleCHIEF OPERATING OFFICER
22,223
0.0814%
$9.32$207,029-35.71%
2024-04-19SaleCHIEF OPERATING OFFICER
22,222
0.082%
$9.34$207,442-35.33%
2024-04-18SaleCHIEF OPERATING OFFICER
44,444
0.1022%
$5.96$265,108-36.90%
2024-04-17SaleCHIEF OPERATING OFFICER
44,444
0.1033%
$6.11$271,553-37.63%
2024-04-16SaleCHIEF OPERATING OFFICER
44,444
0.1006%
$6.29$279,722-41.10%
2024-04-15Saledirector
800
0.003%
$10.45$8,360-41.28%
2024-04-15SaleCHIEF OPERATING OFFICER
44,444
0.1001%
$6.30$280,126-41.28%
2024-04-05SaleCHIEF EXECUTIVE OFFICER
44,300
0.1644%
$10.75$476,269-43.22%

Insider Historical Profitability

97.95%
Andrade RobertCHIEF FINANCIAL OFFICER
104271
0.3802%
$5.99110
Raykov Rostydirector
66432
0.2422%
$5.99117
Butts Robert W
41504000
151.3215%
$5.9910
Southpoint Capital Advisors LP10 percent owner
4077214
14.8653%
$5.9931+14.67%
Essetifin SPA10 percent owner
3993694
14.5608%
$5.9920+12.47%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Southpoint Capital Advisors Lp$45.34M14.924.08M0%+$00.9
Sonic Gp Llc$26.77M8.812.41M0%+$035.88
DG Capital$16.81M5.531.51M+40.54%+$4.85M10.88
Solas Capital Management Llc$12.35M4.061.11M-19.46%-$2.98M7.94
The Vanguard Group$11.27M3.711.01M-11.09%-$1.41M<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.